US2016194379A1PendingUtilityA1

Regeneration of Damaged Tissue

58
Assignee: ELASTAGEN PTY LTDPriority: Aug 13, 2013Filed: Aug 13, 2014Published: Jul 7, 2016
Est. expiryAug 13, 2033(~7.1 yrs left)· nominal 20-yr term from priority
A61P 41/00A61P 17/02A61K 38/39A61K 38/00A61L 27/56A61L 27/22A61K 9/0014A61L 2400/06A61L 27/3633A61K 9/70A61F 13/00063A61F 13/0213A61K 9/06C07K 14/78
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of healing a wound including contacting a wound edge with a tropoelastin or elastin derived peptide in conditions for enabling a sustained contact of the tropoelastin with the wound edge for a time period for enabling re-epithelialization of the wound.

Claims

exact text as granted — not AI-modified
1 . A method of healing a wound including:
 providing an individual having a wound, the wound including a plurality of epidermal cells located about the wound thereby forming a wound edge;   contacting the wound edge with a therapeutically effective amount of tropoelastin in conditions for enabling a sustained contact of the tropoelastin with the wound edge for a time period for enabling re-epithelialization of the wound;   wherein the re-epithelialization of the wound enables healing of the wound;   thereby healing the wound.   
     
     
         2 . The method of  claim 1  wherein the tropoelastin is provided in the form of a gel having a viscosity or an adherence which enables sustained contact of the tropoelastin with the wound edge. 
     
     
         3 . The method of  claim 1  wherein the tropoelastin is provided on an apical surface of a solid phase and said solid phase is placed in a wound bed so that the apical surface of the solid phase is aligned with the wound edge, thereby enabling sustained contact of the tropoelastin with the wound edge. 
     
     
         4 . The method of  claim 3  wherein the solid phase is a dressing, stent, scaffold, bulking agent or prosthesis. 
     
     
         5 . The method of  claim 1  wherein a solution of tropoelastin is sprayed onto a wound edge in conditions enabling evaporation of solvent from the solution, thereby enabling sustained contact of tropoelastin with the wound edge. 
     
     
         6 . The method of  claim 1  wherein the tropoelastin is provided in an amount of about 0.1 mg to 250 mg/ml to the wound edge. 
     
     
         7 . The method of  claim 1  wherein the tropoelastin is provided in sustained contact with the wound edge for a period of no more than about 1 to 2 weeks. 
     
     
         8 . The method of  claim 1  wherein the tropoelastin is not contacted with the wound bed to enable sustained contact of the tropoelastin with the wound bed.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.